Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity

Osteosarcoma

(2016) Patrick J. Messerschmitt et al.   JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS

Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells

(2015) A. M. Carrillo et al.   MOLECULAR CANCER RESEARCH

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

(2015) Pasha Apontes et al.   Oncotarget

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

(2014) Zhuming Zhang et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma

(2014) L Chen et al.   BRITISH JOURNAL OF CANCER

Cisplatin-Induced Testicular Toxicity in Rats: The Protective Effect of Arjunolic Acid

(2014) Iman O. Sherif et al.   JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

(2014) Buyun Ma et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia

(2014) Ingvild Haaland et al.   Molecular Cancer

Radiation enteropathy—pathogenesis, treatment and prevention

(2014) Martin Hauer-Jensen et al.   Nature Reviews Gastroenterology & Hepatology

Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models

(2014) Zhihua Ren et al.   PLoS One

p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy

(2013) B Rao et al.   BRITISH JOURNAL OF CANCER

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling

(2013) K. I. Pishas et al.   CANCER RESEARCH

What’s New in Limb Lengthening and Deformity Correction

(2013) Sanjeev Sabharwal et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cisplatin inhibits bone healing during distraction osteogenesis

(2013) Kimo C. Stine et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

(2013) Zhuming Zhang et al.   ACS Medicinal Chemistry Letters

Differential regulation of p21waf1protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications

(2012) Li-Ju Chang et al.   CANCER BIOLOGY & THERAPY

Over 10-year follow-up of functional outcome in patients with bone tumors reconstructed using distraction osteogenesis

(2012) Koji Watanabe et al.   JOURNAL OF ORTHOPAEDIC SCIENCE

Bone tumor reconstruction with the Ilizarov method

(2012) Thomas H. McCoy et al.   JOURNAL OF SURGICAL ONCOLOGY

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

(2011) Jane M Valentine et al.   BMC CANCER

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

(2011) Hege O Ohnstad et al.   BMC CANCER

Physeal Distraction for Joint Preservation in Malignant Metaphyseal Bone Tumors in Children

(2011) Michael Betz et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Pathobiology and Prevention of Cancer Chemotherapy-Induced Bone Growth Arrest, Bone Loss, and Osteonecrosis

(2011) C. Fan et al.   CURRENT MOLECULAR MEDICINE

Recent Advances in the Therapeutic Perspectives of Nutlin-3

(2011) Paola Secchiero et al.   CURRENT PHARMACEUTICAL DESIGN

Inhibin A enhances bone formation during distraction osteogenesis

(2011) Daniel S. Perrien et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

Application of Beta Regression to Analyze Ischemic Stroke Volume in NINDS rt-PA Clinical Trials

(2011) Christopher J. Swearingen et al.   NEUROEPIDEMIOLOGY

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

Cellular quiescence caused by the Mdm2 inhibitor Nutlin-3A

(2010) Lioubov G. Korotchkina et al.   CELL CYCLE

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53

(2010) C F Cheok et al.   CELL DEATH AND DIFFERENTIATION

Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration

(2010) F. Zhang et al.   DRUG METABOLISM AND DISPOSITION

Emerging drugs for the management of cancer treatment induced bone loss

(2010) Francesco Bertoldo et al.   EXPERT OPINION ON EMERGING DRUGS

Low Bone Mineral Density and High Incidences of Fractures and Vitamin D Deficiency in 52 Pediatric Cancer Survivors

(2010) Kalliopi Bilariki et al.   Hormone Research in Paediatrics

The kinase Mirk is a potential therapeutic target in osteosarcoma

(2009) C. Yang et al.   CARCINOGENESIS

Restoration of regenerative osteoblastogenesis in aged mice: Modulation of TNF

(2009) Elizabeth C Wahl et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Runt-Related Transcription Factor 2 (RUNX2) and RUNX2-Related Osteogenic Genes Are Down-Regulated throughout Osteogenesis in Type 1 Diabetes Mellitus

(2007) John L. Fowlkes et al.   ENDOCRINOLOGY